Results for daraprim

Add to feed Create your own feed

Latest

Shkreli was heard on the recordings discussing ways to prevent a costly drug, Daraprim, from being rendered in generic form at an affordable price.

A federal judge has ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.

Martin Shkreli increased the price of Daraprim from $13.50 to $750 per pill after obtaining exclusive rights to it in 2015

Federal judge: Martin Shkreli must return $64.6 million in profits he and his former company reaped from raising the price of the life-saving drug Daraprim.

A federal judge ruled that Martin Shkreli must return profits he and his former company reaped from raising the price of the life-saving drug Daraprim

A federal judge has ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.

BREAKING: A federal judge ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from practicing in the pharmaceutical industry.

A federal judge ruled that Martin Shkreli must return profits he and his former company reaped from raising the price of the life-saving drug Daraprim.

A federal judge has ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.

A federal judge has ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry for the rest of his life.

Loading
Loading

Most relevant

Martin Shkreli must return $64.6 million US in profits he and his former company reaped from raising the price of the life-saving drug Daraprim.

Shkreli was CEO of Turing Pharmaceuticals — later Vyera — when it jacked up the price of Daraprim. It treats a rare parasitic disease that strikes pregnant women, cancer patients and AIDS patients.

BREAKING: A federal judge ordered Martin Shkreli to return $64.6 million in profits he and his company reaped from inflating the price of the life-saving drug Daraprim and barred him from participating in the pharmaceutical industry.

Martin Shkreli was fined $64.6M for jacking up prices of lifesaving drug Daraprim by over 5,000% — to $750 per pill. The "pharma bro" also blocked creation of generic versions. He is currently serving 7 years in prison for fraud and is banned from the pharma industry for life.

tweet picture

Martin Shkreli must return $64.6 million in profits he and his former company reaped from raising the price of the life-saving drug Daraprim, a federal judge ruled Friday.

‘Pharma Bro’ Martin Shkreli, who made himself a public enemy by hiking the HIV medication Daraprim by over 4,100 percent, has been hit with a nine-figure lawsuit from health insurers

Perhaps the most notorious was Turing Pharmaceuticals buying the rights in 2015 to Daraprim, which is used to treat infections. The company raised the price overnight from $13.50 to $750 a pill

The FDA approved the first generic version of Daraprim, which is used to treat an infection caused by a parasite. The drug came to public attention in 2015 after Turing Pharmaceuticals increased its price from $13.50 to $750 per pill.

Jacking up the price of a lifesaving drug from $17.50 to $750 is brazen&unacceptable. As a result of Shkreli’s anticompetitive practices, patients lost out on generic Daraprim. The FTC was right to bring a case against Vyera for this price gouging behavior.

Loading
Loading